No matter how badly a drug fails in Phase III, investigators and the companies that employ them often bend over backwards to highlight any positive sign of efficacy, no matter how weak the signal. And GlaxoSmithKline’s team at the American College of Cardiology meeting over the weekend was in full spin mode with their heart drug darapladib.

…read more

Source: GlaxoSmithKline’s darapladib team finds hope in a PhIII bomb


0 No comments